JP2005517384A5 - - Google Patents

Download PDF

Info

Publication number
JP2005517384A5
JP2005517384A5 JP2003521777A JP2003521777A JP2005517384A5 JP 2005517384 A5 JP2005517384 A5 JP 2005517384A5 JP 2003521777 A JP2003521777 A JP 2003521777A JP 2003521777 A JP2003521777 A JP 2003521777A JP 2005517384 A5 JP2005517384 A5 JP 2005517384A5
Authority
JP
Japan
Prior art keywords
seq
antibody
lcvr
hcvr
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003521777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005517384A (ja
JP4012880B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/021842 external-priority patent/WO2003016468A2/en
Publication of JP2005517384A publication Critical patent/JP2005517384A/ja
Publication of JP2005517384A5 publication Critical patent/JP2005517384A5/ja
Application granted granted Critical
Publication of JP4012880B2 publication Critical patent/JP4012880B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003521777A 2001-08-16 2002-08-15 拮抗的抗ｈＴＮＦＳＦ１３ｂヒト抗体 Expired - Fee Related JP4012880B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31280801P 2001-08-16 2001-08-16
PCT/US2002/021842 WO2003016468A2 (en) 2001-08-16 2002-08-15 Antagonistic anti-htnfsf13b human antibodies

Publications (3)

Publication Number Publication Date
JP2005517384A JP2005517384A (ja) 2005-06-16
JP2005517384A5 true JP2005517384A5 (https=) 2006-01-05
JP4012880B2 JP4012880B2 (ja) 2007-11-21

Family

ID=23213094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003521777A Expired - Fee Related JP4012880B2 (ja) 2001-08-16 2002-08-15 拮抗的抗ｈＴＮＦＳＦ１３ｂヒト抗体

Country Status (26)

Country Link
US (4) US7317089B2 (https=)
EP (2) EP1432735B1 (https=)
JP (1) JP4012880B2 (https=)
KR (1) KR100961299B1 (https=)
CN (1) CN100497392C (https=)
AR (1) AR035119A1 (https=)
AU (2) AU2002322436C1 (https=)
BR (1) BR0211630A (https=)
CA (1) CA2452447C (https=)
CO (1) CO5560617A2 (https=)
DK (2) DK1432735T3 (https=)
EA (1) EA009074B1 (https=)
EC (1) ECSP044978A (https=)
ES (2) ES2389834T3 (https=)
HR (1) HRP20040147A2 (https=)
HU (1) HU230006B1 (https=)
IL (1) IL160373A0 (https=)
MX (1) MXPA04001344A (https=)
NO (1) NO20040603L (https=)
NZ (1) NZ530657A (https=)
PE (1) PE20030334A1 (https=)
PL (1) PL212404B1 (https=)
PT (2) PT2348048E (https=)
UA (1) UA89017C2 (https=)
WO (1) WO2003016468A2 (https=)
ZA (1) ZA200401154B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001268427B2 (en) * 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
ATE549354T1 (de) * 2001-05-11 2012-03-15 Amgen Inc Peptide und damit zusammenhängende an tall-1 bindende moleküle
WO2006025345A1 (ja) * 2004-08-31 2006-03-09 Kowa Company, Ltd. 抗ヒトｂａｆｆ抗体
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
EA015860B1 (ru) * 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8202698B2 (en) 2005-11-08 2012-06-19 Biogen Idec Ma Inc. Methods of evaluating BAFF
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
US20100189723A1 (en) 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
AR090626A1 (es) 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
HK1209768A1 (en) 2012-07-03 2016-04-08 Washington University Antibodies to tau
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
WO2016039801A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
WO2015187521A2 (en) * 2014-06-03 2015-12-10 Merck Sharp & Dohme Corp. Anti-blys antibodies
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
AR104368A1 (es) * 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN118515767B (zh) * 2024-07-23 2024-10-18 江苏双全生物医药科技有限公司 一种TNFSF13b抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6096878A (en) * 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
ES2248823T5 (es) 1996-10-25 2011-11-03 Human Genome Sciences, Inc. Neutroquina alfa.
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2303424A1 (en) 1997-09-12 1999-03-18 Jurg Tschopp Kay - a novel immune system protein
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US6787638B1 (en) 1998-12-02 2004-09-07 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use
BR0007719A (pt) 1999-01-25 2001-11-13 Biogen Inc Baff, agentes de bloqueio relacionados e uso dosmesmos no estìmulo e na inibição de células b e deimunoglobulinas em respostas imunológicas
NZ513290A (en) 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys

Similar Documents

Publication Publication Date Title
JP2005517384A5 (https=)
CA2452447A1 (en) Antagonistic anti-htnfsf13b human antibodies
RU2445319C2 (ru) Моноклональные антитела к клаудину-18 для лечения рака
JP6998895B2 (ja) Ｌａｇ－３抗体、その抗原結合フラグメント、およびそれらの医薬的用途
JP2023065391A (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
JP2022031635A5 (https=)
JP2022105178A (ja) 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）感染症を治療および予防するための組成物および方法
KR100872210B1 (ko) 인터페론 알파 수용체-1 (ｉｆｎａｒ-1)에 대한 인체화항체
JP2012526558A5 (https=)
RU2009128064A (ru) Антитела к cd44
RU2021133819A (ru) Анти-lag-3 антитела
JP2017079785A5 (https=)
RU2009135824A (ru) Антитела-антагонисты против ох40 и их применение в лечении воспалительных и аутоиммунных заболеваний
JP2014525933A5 (https=)
JP7766392B2 (ja) 治療用抗ｃｄ４０リガンド抗体
JP2018537400A5 (https=)
RU2011101969A (ru) Антитела к человеческому интерлейкину-20
JP2011514150A5 (https=)
JP2007530551A5 (https=)
JP2002501085A5 (https=)
KR20170020477A (ko) 인터페론 알파 및 오메가 항체 길항제
RU2016122340A (ru) Il-17a-связующий агент и способы его применения
Salemi et al. The expanding role of therapeutic antibodies
JP2009502952A5 (https=)
JP2013519690A5 (https=)